Seattle Genetics Seeks To “Change The Treatment Paradigm” For Non-Hodgkin’s Lymphoma
This article was originally published in The Pink Sheet Daily
Executive Summary
Registration path for SGN-40, partnered with Genentech, could be through front-line treatment of aggressive NHL.
You may also be interested in...
Genentech Gets Non-Hodgkin’s Lymphoma Candidate With Seattle Genetics Deal
SGN-40 will be examined for potential use with and without Rituxan.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.